Whereas enrichment of ERBB3 co-alteration was maintained in MSS GEC (10.8% MUT vs. 3.6% WT; P < 0.001), this enrichment became non-significant in MSS CRC (3.1% MUT vs. 1.7% WT; P = 0.07), suggesting that ERBB3 co-alteration could be MSI/TMB-associated in some cancers (Supplementary Fig. S8F and S8G and consistent with Table 1). This evidence concerns the gene ERBB3 and cancer.